Photo furnished by Alltech
Researchers with Alltech Life Sciences have announced the development of a possible alternative to current insulin treatments for hundreds of millions of patients worldwide who are living with diabetes.
The results from 12 years of scientific research were recently published in the peer-reviewed journal Cellular and Molecular Life Sciences. The paper details the development of a novel treatment for both Type 1 and Type 2 diabetes, using a compound called NPC43.
The compound works by reactivating dormant insulin receptors, thereby allowing blood glucose to enter cells. Furthermore, it inhibits glucose production from diabetic liver — a condition associated with insulin resistance that worsens the problem of having excess glucose in the bloodstream. NPC43 is effective when administered either orally or by injection.
“Imagine insulin to be a key and an insulin receptor to be a lock that allows glucose to enter cells,” explained Dr. Ronan Power, chief scientific officer at Alltech, in a release announcing the breakthrough. “Type 1 diabetics can’t produce keys and, although Type 2 diabetics can, they possess broken locks. The result of either type is that the glucose door remains shut. What we have discovered is a way to open the lock without a key, even if the lock is broken.”
In addition to enduring the pain and anxiety of injections, those living with diabetes are often faced with limited access to affordable treatment. Insulin prices have more than tripled in the last 10 years, becoming unattainable for most underinsured patients.
“The compound has the potential to be revolutionary,” said Dr. Zi-Jian Lan, senior research scientist with Alltech Life Sciences. “Since it works when administered orally, this could mean the elimination of injections, pens and pumps, and provide an affordable alternative to insulin.”
The implications for NPC43 could extend beyond diabetes to any syndrome or disease associated with insulin resistance. That may include polycystic ovary syndrome (PCOS), cardiovascular disease, obesity and non-alcoholic fatty liver disease.
The research was conducted in cultured human cells and in animal models of severe Type 2 diabetes. The next milestone in the development of NPC43 will be clinical trials. Alltech, Inc. has filed an international patent application covering this technology (PCT/US18/30371).